BioSpace News Archive

Antibe Therapeutics Inc., a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for inflammation arising from a wide range of medical conditions, is pleased to announce its participation in the Bloom Burton & Co. Healthcare Investor Conference being held virtually on Tuesday, April 20 and Wednesday, April 21.

TSHA-113 significantly reduced tau mRNA and protein levels in mouse models of human tauopathies via cerebral spinal fluid (CSF) delivery supporting further preclinical development

Lexaria Bioscience Corp. announced that its corporate client Amari Corp.'s “Everyday Calm” CBD product was named a Top CBD Product Pick by New Hope Network

Inozyme Pharma, Inc. , a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today presented data that highlight the burden of disease for patients and families affected by ENPP1 Deficiency and ABCC6 Deficiency, two devastating and potentially deadly genetic diseases. In a poster entitled,

Ms. Maldonado to Oversee Manufacturing Development of Codagenix’s Vaccines as Clinical Trials for COVID-19, RSV and Flu Progress

Aldevron, the world’s leading biomanufacturer of plasmid DNA, mRNA and proteins, is expanding its commercial leadership with the addition of Beth Thompson-Webb as Chief Commercial Officer and Todd Howren as Vice President of Sales.

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, and Lonza today announced that the companies have entered into an agreement for the manufacture of ATYR2810, aTyr’s monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical development for cancer.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has started dosing in the first cohort of chronic hepatitis B (CHB) patients in the ongoing ALG-000184-201 study (NCT04536337).

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate and host 1:1 meetings at the virtual Kempen Life Science Conference, taking place April 21, 2021.